CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¹®¿ëÈ­
  • Ç÷¾×Á¾¾ç³»°úÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : À¯¹æ¾Ï, ºÎÀξÏ, Àü¸³¼±¾Ï
  • Á÷ À§: ±³¼ö(Ç÷¾×Á¾¾ç³»°úÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

µî·Ï

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ ´Ù¿î·Îµå
8 ÇØ¿Ü Sohn JH*, Moon YW*, Lee CG, et al.. Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. (*Both equally contributed) Cancer 109:1845-1850, 2007  
7 ÇØ¿Ü Moon YW, Jeung H-C, Rha SY, et al.. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Breast Cancer Res Treat 104:31-37, 2007  
6 ÇØ¿Ü Moon YW, Jeung H-C, Rha SY, et al.. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. Ann Surg Oncol 14:2730-2737, 2007  
5 ±¹³» Moon YW, Choi ST, Cho BC, et al.. A case of successful intrapleural chemotherapy with cisplatin plus cytarabine for intractable malignant pleural effusion. Yonsei Med J 48:1035-1038, 2007  
4 ÇØ¿Ü Sohn JH, Choi HJ, Chang J, Kim SK, Lee CG, Chung KY, Kim DJ, Cho BC, Shin SJ, Moon YW, et al.. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. Lung Cancer 54:365-370, 2006  
3 ÇØ¿Ü Rha SY, Moon YH, Jeung H-C, et al.. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90:215-221, 2005  
2 ±¹³» Moon YW, Hahn JS, Lee ST, et al.. Clinical characteristics and treatment outcome of primary mediastinal lymphoma. Korean J Med 68:417 426, 2005 (Korean)  
1 ±¹³» Moon YW, Yang H, Jung HC, et al.. Application of gabexate mesylate IC50 against MMP - 9 using ex vivo model in gastric cancer: prognostic factor and selection criteria for anti - MMP treatment. J Korean Cancer Assoc 32:7-18, 2000 (Korean)  
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729